Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 23, 2026	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021
Market Capitalization	23	17	62	8	18	35
Market Cap Growth	-8.31%	-72.15%	627.66%	-51.77%	-50.18%	13.53%
Enterprise Value	18	12	53	5	10	27
Last Close Price	0.97	0.88	3.91	1.05	2.96	6.22
PS Ratio	61.97	24.39	133.15	37.56	68.97	48.92
PB Ratio	3.66	6.62	8.07	3.17	2.31	2.71
P/TBV Ratio	3.63	6.42	8.22	3.29	2.36	2.74
EV/Sales Ratio	47.91	17.46	114.33	21.58	39.44	37.19
Debt / Equity Ratio	0.02	0.04	0.02	0.06	0.01	0.01
Net Debt / Equity Ratio	-0.83	-0.71	-0.84	-0.49	-0.80	-0.89
Net Debt / EBITDA Ratio	0.57	0.16	1.14	0.21	0.94	2.09
Net Debt / FCF Ratio	0.55	0.18	1.28	0.22	1.24	2.92
Asset Turnover	0.05	0.11	0.08	0.04	0.02	0.09
Inventory Turnover	-	-	-	-	2.11	2.39
Quick Ratio	24.74	1.56	6.10	5.99	32.79	78.90
Current Ratio	26.88	2.32	7.18	8.04	35.96	81.18
Return on Equity (ROE)	-147.07%	-232.15%	-112.36%	-130.18%	-71.35%	-73.16%
Return on Assets (ROA)	-75.98%	-111.49%	-59.56%	-73.59%	-39.21%	-44.17%
Return on Capital Employed (ROCE)	-146.90%	-433.80%	-73.30%	-228.20%	-86.60%	-43.40%
Earnings Yield	-41.79%	-69.13%	-9.38%	-78.45%	-41.27%	-11.39%
FCF Yield	-41.29%	-60.84%	-8.09%	-69.63%	-27.98%	-11.28%
Buyback Yield / Dilution	-31.30%	-45.34%	-87.24%	-12.38%	-34.02%	-58.34%

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q